BlackRock’s Translate Bio, Inc. Common Stock TBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-5,552,786
| Closed | -$153M | – | 5744 |
|
|
2021
Q2 | $153M | Sell |
5,552,786
-154,626
| -3% | -$3.04M | ﹤0.01% | 1974 |
|
|
2021
Q1 | $94.1M | Buy |
5,707,412
+266,772
| +5% | +$6.08M | ﹤0.01% | 2231 |
|
|
2020
Q4 | $100M | Buy |
5,440,640
+147,768
| +3% | +$2.64M | ﹤0.01% | 2083 |
|
|
2020
Q3 | $72M | Buy |
5,292,872
+614,248
| +13% | +$9.47M | ﹤0.01% | 2085 |
|
|
2020
Q2 | $83.8M | Buy |
4,678,624
+1,485,566
| +47% | +$22.4M | ﹤0.01% | 1950 |
|
|
2020
Q1 | $31.8M | Buy |
3,193,058
+34,487
| +1% | +$283K | ﹤0.01% | 2342 |
|
|
2019
Q4 | $25.7M | Buy |
3,158,571
+374,172
| +13% | +$3.45M | ﹤0.01% | 2742 |
|
|
2019
Q3 | $27.6M | Buy |
2,784,399
+269,007
| +11% | +$2.54M | ﹤0.01% | 2628 |
|
|
2019
Q2 | $31.8M | Buy |
2,515,392
+549,817
| +28% | +$5.8M | ﹤0.01% | 2582 |
|
|
2019
Q1 | $20M | Buy |
1,965,575
+983,170
| +100% | +$7.54M | ﹤0.01% | 2752 |
|
|
2018
Q4 | $7.37M | Buy |
982,405
+555,635
| +130% | +$4.07M | ﹤0.01% | 3233 |
|
|
2018
Q3 | $4.27M | Buy |
426,770
+276,715
| +184% | +$3.22M | ﹤0.01% | 3547 |
|
|
2018
Q2 | $1.9M | Buy |
+150,055
| New | +$1.81M | ﹤0.01% | 3761 |
|
BlackRock's TBIO Position: Q3 2021 in Review
BlackRock sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 5,552,786 shares — an estimated $153M sold.
BlackRock first reported a position in TBIO in Q2 2018 and held it in 13 quarters. The position peaked at $153M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.
- BlackRock reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
- BlackRock sold 5,552,786 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $153M.
- BlackRock first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
- BlackRock's Translate Bio, Inc. Common Stock position peaked at $153M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.
Based on BlackRock's 13F filing for Q3 2021, filed 9 Nov 2021.